Biotechnology - Clinical-stage immunotherapies (Immuno-Oncology and Immuno-Inflammation)
Strategic Profile
As of March 2026, the company has announced a targeted realignment of its R&D portfolio, pausing development of OSE-230 to focus resources on late-stage, high-potential assets lusvertikimab and Tedopi®. These two assets are expected to generate multiple clinical catalysts over the next three years. The company continues to explore various options, including business development, strategic alliances, international investments, and a potential Nasdaq listing.
Cyborg Score Rationale
OSE demonstrates solid scientific credentials and progressing late-stage assets (Tedopi Phase 3, lusvertikimab expanding indications), with recent partnerships (Boehringer Ingelheim, French government mRNA funding). However, the company faces capital constraints, recent portfolio streamlining, and is dependent on regulatory and clinical milestones through 2028 for value creation.
Top Insights
March 2026: Portfolio streamlining with focus on two cornerstone assets—lusvertikimab for inflammatory indications and Tedopi® cancer vaccine for NSCLC.
Strategic positioning includes €90M+ in non-dilutive funding secured and partnerships with major pharma (Boehringer Ingelheim, AbbVie) plus French government mRNA development support.
Capital-efficient focus: Discontinued early-stage programs without expected near-term value inflection, concentrating resources on late-stage assets and reducing financial runway pressure.
Named Competitors
Various immuno-oncology programs — French competitor developing immunotherapies
T-cell redirecting therapies — Cell therapy and immunotherapy development
CAR-NK and checkpoint inhibitor combos — Cell and checkpoint immunotherapy company
Novel oncology immunotherapies — European biotech with oncology focus
Recent Developments
(March 2026) Announced strategic portfolio realignment focusing on lusvertikimab and Tedopi®, pausing OSE-230 development
(January 2026) Selected chronic pouchitis and hidradenitis suppurativa as new target indications for lusvertikimab
(June 2025) Strengthened growth strategy with €90M+ in non-dilutive funding and focus on two-pillar Inflammation and Immuno-Oncology programs
(May 2025) Secured €1.3M French government funding for HexARN mRNA therapeutic development program
Open the full interactive OSE Immunotherapeutics report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.